Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.
2.

Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.

Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ.

J Neurochem. 2005 Aug;94(4):1087-101. Epub 2005 Jun 30.

4.

Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons.

Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Néri C.

Nat Genet. 2005 Apr;37(4):349-50. Epub 2005 Mar 27. Erratum in: Nat Genet. 2005 May;37(5):555.

PMID:
15793589
5.

Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.

Wang X, Sarkar A, Cicchetti F, Yu M, Zhu A, Jokivarsi K, Saint-Pierre M, Brownell AL.

J Neurol Sci. 2005 Apr 15;231(1-2):57-66. Epub 2005 Jan 28.

PMID:
15792822
6.

Mechanism for the inhibition of transglutaminase 2 by cystamine.

Jeitner TM, Delikatny EJ, Ahlqvist J, Capper H, Cooper AJ.

Biochem Pharmacol. 2005 Mar 15;69(6):961-70.

PMID:
15748707
7.

Modulation of neurodegeneration by molecular chaperones.

Muchowski PJ, Wacker JL.

Nat Rev Neurosci. 2005 Jan;6(1):11-22. Review.

PMID:
15611723
9.

Huntingtin interacting protein 1 (HIP1) regulates clathrin assembly through direct binding to the regulatory region of the clathrin light chain.

Legendre-Guillemin V, Metzler M, Lemaire JF, Philie J, Gan L, Hayden MR, McPherson PS.

J Biol Chem. 2005 Feb 18;280(7):6101-8. Epub 2004 Nov 8.

11.

Long-term follow-up of well-treated nephropathic cystinosis patients.

Kleta R, Bernardini I, Ueda M, Varade WS, Phornphutkul C, Krasnewich D, Gahl WA.

J Pediatr. 2004 Oct;145(4):555-60.

PMID:
15480385
12.

Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.

Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, Buzescu R, Chopra R, Ferrante RJ, Kazantsev A, Hersch SM.

J Neurochem. 2004 Oct;91(2):413-22.

13.

Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.

Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martín-Ibañez R, Muñoz MT, Mengod G, Ernfors P, Alberch J.

J Neurosci. 2004 Sep 1;24(35):7727-39.

14.

Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB.

Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS.

Nature. 2004 Aug 26;430(7003):1034-9.

15.

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules.

Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F.

Cell. 2004 Jul 9;118(1):127-38.

16.

Domains of the TGN: coats, tethers and G proteins.

Gleeson PA, Lock JG, Luke MR, Stow JL.

Traffic. 2004 May;5(5):315-26. Review.

17.

Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.

Belldina EB, Huang MY, Schneider JA, Brundage RC, Tracy TS.

Br J Clin Pharmacol. 2003 Nov;56(5):520-5.

18.

Huntington's disease.

MacDonald ME, Gines S, Gusella JF, Wheeler VC.

Neuromolecular Med. 2003;4(1-2):7-20. Review.

PMID:
14528049
19.

The hunt for huntingtin function: interaction partners tell many different stories.

Harjes P, Wanker EE.

Trends Biochem Sci. 2003 Aug;28(8):425-33. Review.

PMID:
12932731
20.

Glutamate-induced increases in transglutaminase activity in primary cultures of astroglial cells.

Campisi A, Caccamo D, Raciti G, Cannavò G, Macaione V, Currò M, Macaione S, Vanella A, Ientile R.

Brain Res. 2003 Jul 18;978(1-2):24-30.

PMID:
12834894

Supplemental Content

Support Center